APRIL:
- Multi-Center Study finds KidneyIntelX 72% more effective than the current standard of care in identifying early-stage patients at higher risk for disease progression and failure
- Clinical Utility Study demonstrates that primary care physicians highly likely to order KidneyIntelX to inform care decisions
- Renalytix and Joslin Diabetes Center enter exclusive option agreement for patent filings on select additional novel biomarkers in kidney disease for development and deployment in the KidneyIntelX platform
- KidneyIntelX demonstrates performance and informs treatment decisions in multinational CANagliflozin CardioVAScular Assessment Study (CANVAS)
- U.S. General Services Administration grants 10-year governmentwide contract for KidneyIntelX testing
MAY:
- Renalytix partners with Atrium Health, Wake Forest Baptist Health and Wake Forest School of Medicine to reduce impact of kidney disease in large populations
JUNE:
- Utility Study indicates KidneyIntelX risk assessment can address treatment ambiguity in primary care
- Renalytix announces new data demonstrating that KidneyIntelX can be effective at monitoring SGLT2 therapeutic response and improvements in kidney health over time in adults with Type 2 diabetes
